| Literature DB >> 33855234 |
Yik-Ling Chew1, Mei-Ann Khor1, Yau-Yan Lim2.
Abstract
Stability indicating assay describes a technique which is used to analyse the stability of drug substance or active pharmaceutical ingredient (API) in bulk drug and pharmaceutical products. Stability indicating assay must be properly validated as per ICH guidelines. The important components in a stability indicating assay include sensitivity, specificity, accuracy, reliability, reproducibility and robustness. A validated assay is able to measure the concentration changes of drug substance/API with time and make reliable estimation of the quantity of the degradation impurities. The drug substance is separated and resolved from the impurities. Pros and cons of HPLC, GC, HPTLC, CE and SFC were discussed and reviewed. Stability indicating assay may consist of the combination of chromatographic separation and spectroscopic detection techniques. Hyphenated system could demonstrate parallel quantitative and qualitative analysis of drug substances and impurities. Examples are HPLC-DAD, HPLC-FL, GC-MS, LC-MS and LC-NMR. The analytes in the samples are separated in the chromatography while the impurities are chemically characterised by the spectroscopy in the system. In this review, various chromatographic methods which had been employed as stability indicating assays for drug substance and pharmaceutical formulation were systematically reviewed, and the application of hyphenated techniques in impurities characterisation and identification were also discussed with supporting literatures.Entities:
Keywords: Degradation; Drug stability; Forced degradation; Impurities; Pharmaceutical; Stability
Year: 2021 PMID: 33855234 PMCID: PMC8027279 DOI: 10.1016/j.heliyon.2021.e06553
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Stability indicating assays for pharmaceutical products.
Stability indicating methods for drug substances and their elution conditions.
| Analytical methods | Drug substances | Elution conditions | References |
|---|---|---|---|
| Elution mode; Mobile phase | |||
| High performance liquid chromatography (HPLC) | Ezetimibe | Gradient elution; ammonium acetate buffer (pH 7.0) and acetonitrile | ( |
| Losartan potassium and hydrochlorothiazide | Gradient elution; phosphate buffer solution of (pH 7.0), with acetonitrile | ( | |
| Atorvastatin and amlodipine | Isocratic elution; acetonitrile-NaH2PO4 buffer (pH 4.5) | ( | |
| Docetaxel | Gradient elution; water-acetonitrile | ( | |
| Glucosamine | Isocratic elution; acetonitrile-phosphate buffer (pH 7.5) | ( | |
| Sacubitril and valsartan | Isocratic elution; acetonitrile-citrate buffer (pH 3) | ( | |
| Sacubitril and valsartan | Isocratic elution; trifluoroacetic acid in water-methanol | ( | |
| Sacubitril and valsartan | Isocratic elution; potassium phosphate buffer (pH 3.0)-methanol | ( | |
| Sacubitril and valsartan | Isocratic elution; acetonitrile-methanol-potassium dihydrogen phosphate (pH 3.8) | ( | |
| Sacubitril and valsartan | Isocratic elution; ammonium acetate buffer (pH 4)-acetonitrile | ( | |
| Vancomycin hydrochloride | Isocratic elution; buffer citrate (pH 4)-acetonitrile-methanol | ( | |
| Curcumin | Isocratic elution; acetonitrile-methanol-water (pH 3) | ( | |
| Excedrin (acetaminophen, aspirin, and caffeine) | Gradient elution; trifluoracetic acid and mixture of trifluoracetic acid-methanol-acetonitrile | ( | |
| Flibanserin | Isocratic elution; ammonium acetate buffer (pH 3) and acetonitrile | ( | |
| Enrofloxacin and piroxicam | Isocratic elution; acetonitrile and water (pH 3) | ( | |
| Carrier gas | |||
| Gas chromatography (GC) | Rosmarinic acid | Helium | ( |
| Divalproex sodium | Helium | ( | |
| Acetaminophen and aspirin | Nitrogen | ( | |
| Magnesium valproate | ( | ||
| Memantine hydrochloride | Nitrogen | ( | |
| Mobile phase composition | |||
| High performance thin layer chromatography (HPTLC) | Curcumin | Chloroform:methanol (9.25:0.75 v/v) | ( |
| Pseudoephedrine and cetirizine | Ethyl acetate–methanol–ammonia (7:1.5:1, v/v/v) | ( | |
| Trimetazidine | N-butanol-water-methanol-ammonia (20%) (14:0.2:0.2:2, v/v/v/v) | ( | |
| Timolol maleate | Ethyl acetate–methanol–isopropyl alcohol–ammonia (25%) (80:20:2:1, v/v/v/v) | ( | |
| Piroxicam | Toluene–acetic acid (8:2 v/v) | ( | |
| Ezetimibe and simvastatin | N-hexane–acetone 6:4 (v/v) | ( | |
| Estradiol | Chloroform–acetone–isopropyl alcohol–glacial acetic acid (9:1:0.4:0.1, v/v/v/v) | ( | |
| Isoniazid and rifampicin | N-hexane–2-propanol–acetone–ammonia–formic acid, 3:3.8:2.8:0.3:0.1 (v/v) | ( | |
| Aspirin and clopidogrel bisulphate | Carbon tetrachloride-acetone (6: 2.4 v/v). | ( | |
| Dabigatran etexilate mesylate | Toluene: ethyl acetate: methanol: formic acid (3:4:3:0.2, v/v/v/v) | ( | |
| Mangiferin | Ethyl acetate: ethanol: formic acid (10:1.5:1v/v/v) | ( | |
| Empagliflozin and Linagliptin | Methanol: toluene: ethyl acetate (2: 4: 4v/v/v) | ( | |
| Saxagliptin | Toluene: methanol: ammonia (6:4:0.2 v/v/v) | ( | |
| Diphenhydramine | Ammonia: methanol: ethyl acetate (2.5 : 5: 42.5 v/v/v) | ( | |
| Column; background electrolyte (BGE) | |||
| Capillary electrophoresis (CE) | Metformin hydrochloride | Fused silica capillaries; citrate buffer (40 mM, pH 6.7) | ( |
| Metformin hydrochloride, saxagliptin hydrochloride, and dapagliflozin | Deactivated fused silica capillary; phosphate buffer (30 mM, pH 6.0) | ( | |
| Tramadol | Uncoated fused-silica capillary; borate buffer (50 mM, pH 10.2) | ( | |
| Amlodipine | Fused-silica capillary; phosphate running buffer (100 mM, pH 3.0) | ( | |
| Buserelin | Bare fused silica capillary, phosphate buffer (pH = 3.00; 26.4 mM) | ( | |
| gemifloxacin and lomefloxacin | Fused silica capillary; H3PO4–NaOH running buffer (25 mM; pH 8.5) | ( | |
| Norfloxacin | Fused-silica capillary; phosphate (10 mM; pH 2.5) | ( | |
| Carvedilol and hydrochlorothiazide | Fused silica capillary; phosphate buffer (12.5 mM; pH 7.4)–methanol (95 + 5, v/v) | ( | |
| Isradipine | Fused-silica uncoated capillary; borate buffer (15 mM; pH 9.3) | ( | |
| Column; elution mode; mobile phase | |||
| Super critical fluid chromatography (SFC) | Clofarabine | Ethylene bridged hybrid 2-ethylpyridine (BEH 2-EP) column; isocratic elution; liquid CO2 and methanol (70:30 v/v) | ( |
| Mometasone furoate | Silica column; gradient elution; liquid CO2 and methanol (5–15% methanol) | ( | |
Comparison of the various analytical methods on the basis of various parameters in pharmaceutical drugs analysis.
| Analytical methods | Application in pharmaceutical drugs | Mobile phases | Sensitivity | Analyst's skills required | Cost | Environment friendly |
|---|---|---|---|---|---|---|
| High performance liquid chromatography (HPLC) | Compounds with diverse polarity, molecular mass, volatility and thermal sensitivity | Liquid | High to ultra-high | High to very high | Moderate to high | No |
| Gas chromatography (GC) | Volatile samples, compounds only, non-chromophoric substances | Gas | High to ultra-high | High to very high | Moderate | Yes |
| High performance thin layer chromatography (HPTLC) | Polar and non-polar compounds, suspension samples | Liquid | Moderate to ultra-high | High | Moderate | Yes |
| Capillary electrophoresis (CE) | Thermally unstable compounds, chiral molecules, water insoluble, charged and neutral drug substances | Liquid | High | High to very high | Moderate | Yes |
| Super critical fluid chromatography (SFC) | Compounds with high solubility in organic solvents, thermally unstable, high molecular weight | Gas | High | High to very high | Moderate | Yes |
Figure 2The principle of the HPLC-DAD data set. Reproduced from Cui et al. (2014). Figure reproduced is under Creative Commons Attribution License.
Figure 3Operation mode of LC-NMR. Reproduced from Exarchou et al. (2005). Figure reproduced with permission from John Wiley & Sons.